Regenerative Medicine for Knee Pain: What Evidence Exists and What Remains Unproven?
- LeNae Goolsby
- 1 hour ago
- 10 min read
Knee pain has a way of shrinking your life one decision at a time. You stop taking the stairs. You avoid the trip that requires too much walking. You think twice before getting on the floor with your grandchildren because getting back up may hurt.
When exercise, medication, physical therapy, or conventional injections have not provided enough relief, “regenerative medicine” can sound like the answer—especially when advertisements promise rebuilt cartilage, a new knee without surgery, or permanent pain relief.
The science is more complicated.
Some regenerative procedures have human studies suggesting possible improvement in pain or function. Others are supported mainly by laboratory or animal research. Products marketed under the same name may contain very different materials. Most importantly, no regenerative medicine product is FDA-approved to treat knee osteoarthritis or knee pain.
That does not make every procedure identical or every study meaningless. It means patients deserve a product-specific, diagnosis-specific discussion of the evidence, uncertainty, cost, and risk.
At Infinite Health Integrative Medicine Center in Metairie, regenerative medicine is approached as a medical decision—not a miracle claim. The first question is not “Which injection do you want?” It is “What is causing your knee pain, and what outcome is medically realistic?”
The Short Answer: Does Regenerative Medicine Work for Knee Pain?
The most accurate answer is: some approaches may improve symptoms for some patients, but the strength of evidence varies considerably, and tissue regeneration has not been reliably demonstrated.
Research is difficult to interpret because studies differ in:
The exact diagnosis and severity of knee disease
The material injected
How the product was collected, processed, stored, and characterized
The dose and number of injections
Whether injections were placed inside the joint, around ligaments, or both
The comparison treatment
Whether patients and researchers were blinded
Follow-up length and outcome measures
This is why “stem cell therapy works” or “regenerative injections do not work” are both overly broad statements. A treatment name is not enough to identify what was studied—or what a clinic is actually offering.
First, Identify the Cause of the Knee Pain
“Knee pain” is a symptom, not a diagnosis. Possible causes include:
Osteoarthritis
Meniscus injury
Ligament or tendon injury
Patellofemoral pain
Bursitis
Inflammatory arthritis
Referred pain from the hip or spine
Fracture, infection, gout, or another condition requiring different care
Most regenerative knee research focuses on osteoarthritis. Results from an osteoarthritis study cannot automatically be applied to an acute ligament tear, advanced deformity, infection, or pain coming from somewhere else.
A responsible evaluation may include a physical examination, review of prior treatment, assessment of strength and movement, and imaging when it could change the plan. Red flags—such as a hot swollen joint, fever, inability to bear weight after trauma, or a suddenly locked knee—may require urgent or conventional orthopedic care rather than an elective injection.
“Regenerative Medicine” Is Not One Treatment
The term is used for several fundamentally different procedures and products. They should not be treated as interchangeable.
Approach | What it generally refers to | What the evidence suggests | What remains unproven |
Dextrose prolotherapy | Hypertonic dextrose injected into or around painful joint structures | Some trials and reviews report pain and function improvements, but studies are small and protocols vary | Cartilage regrowth, disease reversal, and predictable long-term benefit |
Cell-based injections | Autologous or donor-derived preparations that may contain or be described as mesenchymal stromal cells | Some studies show symptom improvement; other rigorous analyses find little or no clinically important advantage over controls | A standardized effect, best cell source or dose, durable structural repair, and prevention of knee replacement |
Wharton’s Jelly–derived products | Donor-derived umbilical-cord connective-tissue products; composition varies by product and processing | Early studies are small and often uncontrolled; product-to-product findings cannot be assumed | That a specific commercial product contains viable stem cells, rebuilds cartilage, or reliably improves knee osteoarthritis |
Exosomes or extracellular vesicles | Cell-released particles proposed to carry signaling molecules | Much of the knee osteoarthritis evidence remains preclinical, including animal studies | Clinical effectiveness, optimal dose, long-term safety, and cartilage regeneration in humans |
What the Evidence Says About Prolotherapy
Dextrose prolotherapy has been studied longer than many cell- or exosome-based approaches. In knee osteoarthritis trials, hypertonic dextrose is injected according to varying protocols, sometimes inside the joint and sometimes around supporting structures.
Several randomized trials and systematic reviews have reported improvements in pain and function. A 2022 meta-analysis of 14 trials involving 978 participants found favorable results compared with placebo or noninvasive controls. However, the authors cautioned that substantial differences among studies and risk of bias limited confidence in the findings.
The 2019 American College of Rheumatology/Arthritis Foundation guideline conditionally recommended against prolotherapy for knee or hip osteoarthritis because the evidence involved relatively few participants, small effects, and inconsistent injection schedules and techniques.
Those positions are not necessarily contradictory. The research contains a signal of possible symptomatic benefit, but it is not strong or standardized enough to support guarantees.
What patients should not be told is that dextrose prolotherapy has been proven to regrow knee cartilage, reverse osteoarthritis, or eliminate the possibility of future surgery. Current evidence does not establish those outcomes.
What the Evidence Says About Mesenchymal Stromal Cell Injections
The phrase “stem cell injection” is often used as though it describes a single treatment. It does not.
Studies have evaluated preparations derived from bone marrow, adipose tissue, and birth tissues. Some involve cells collected from the patient; others involve donors. Some cells are isolated or expanded in a laboratory. Cell counts, viability, processing, accompanying substances, and regulatory status differ.
This heterogeneity helps explain why reviews reach different conclusions.
Some meta-analyses report better pain scores after mesenchymal stromal cell injections. Others that focus on placebo-controlled evidence find little to no meaningful improvement in pain or physical function. A 2024 systematic review in Osteoarthritis and Cartilage concluded that intra-articular MSC injections probably provide little to no improvement for chronic knee pain associated with osteoarthritis. A 2025 review also found that much of the observed symptom improvement may reflect contextual or placebo effects, with only a modest incremental benefit and low-certainty evidence.
The American College of Rheumatology/Arthritis Foundation strongly recommends against stem cell injections for knee and hip osteoarthritis because of product heterogeneity and lack of standardization. The American Academy of Orthopaedic Surgeons likewise states that evidence for stem cell treatment in orthopedic conditions remains limited and mixed.
Most crucially, pain improvement is not proof of cartilage regeneration. A patient may feel better without measurable structural repair, while an imaging change may not necessarily produce a meaningful improvement in daily function.
What We Know About Wharton’s Jelly–Derived Products
Wharton’s Jelly is connective tissue within the umbilical cord. Commercially available products described as Wharton’s Jelly may differ significantly depending on donor screening, collection, processing, preservation, sterilization, and final composition.
“Wharton’s Jelly” does not automatically mean “living stem cells.” A product might be described as a tissue matrix, structural tissue product, cellular product, or source of extracellular components. Those distinctions matter scientifically and legally.
The published human knee literature includes small observational studies and early clinical investigations. Some report symptom improvements, but small samples, lack of placebo controls, potential conflicts, and product variability make it impossible to generalize those findings to every Wharton’s Jelly–derived product.
The FDA states that regenerative medicine products, including products derived from umbilical cord tissue, have not been approved to treat orthopedic conditions such as knee pain or osteoarthritis. Any claim about a particular product should therefore be tied to its actual composition, manufacturing information, regulatory status, and directly applicable evidence.
It is not scientifically responsible to assume that every Wharton’s Jelly product is a stem-cell product—or that findings from cultured umbilical-cord cells apply to a differently processed commercial tissue product.
What the Evidence Says About Exosomes
Exosomes are small extracellular vesicles released by cells. Researchers are studying whether the signals they carry might influence inflammation and tissue behavior.
This is a promising research area, but promise is not proof.
Much of the favorable knee osteoarthritis evidence comes from laboratory and animal models. For example, a 2025 systematic review and meta-analysis evaluated mesenchymal stromal cell–derived exosomes in rat models—not established clinical treatment in humans.
There are currently no FDA-approved exosome products. Human evidence has not established an optimal source, dose, manufacturing standard, delivery method, treatment schedule, or long-term safety profile for knee osteoarthritis.
Claims that exosomes “regrow cartilage,” “repair the knee,” or “work like stem cells without the risk” move far beyond what clinical evidence has established.
What the FDA Status Actually Means
FDA approval is product- and indication-specific. A product being registered, processed in a laboratory, obtained from donated tissue, or used by a medical practice does not mean the FDA has approved it to treat knee pain.
The FDA’s consumer information states that regenerative medicine products—including stem cell products, exosome products, and certain umbilical-cord-derived products—have not been approved for orthopedic conditions such as osteoarthritis or knee pain.
Patients should ask:
What is the exact name and source of the product?
What does testing confirm is present in the final product?
Is this specific product FDA-approved for knee osteoarthritis?
If it is investigational, is it being administered under an FDA-authorized investigational new drug application or clinical trial?
Which published human studies evaluated this same product and protocol?
What adverse events have been reported?
Who manufactures and handles the product?
What outcome is realistic—and what cannot be promised?
A transparent clinician should be willing to answer these questions without substituting testimonials for data.
What Risks Should Be Discussed?
The risk profile depends on the procedure and product. Potential risks can include:
Temporary pain, swelling, or stiffness
Bleeding or bruising
Infection
Injury to nearby structures
Allergic or inflammatory reactions
Immune reactions or disease-transmission concerns with donor-derived products
Contamination or inconsistency related to processing and handling
Financial harm from paying for an expensive treatment that does not help
Delayed diagnosis or delayed treatment of a condition that needs different care
“Natural,” “cell-free,” “birth tissue,” and “minimally invasive” are not substitutes for safety data.
What Does an Evidence-Informed Knee Plan Look Like?
Regenerative medicine should not exist in a vacuum. A complete knee plan may include:
A diagnosis specific enough to guide treatment
Strength, mobility, and gait assessment
Progressive therapeutic exercise
Weight management when excess load contributes to symptoms
Activity modification without unnecessary deconditioning
Appropriate bracing or assistive devices
Medication options based on medical history
Conventional injections when indicated
Regenerative procedures only after a transparent evidence and risk discussion
Orthopedic referral when structural disease or symptom severity warrants it
Exercise, strength training, and weight management have stronger guideline support for knee osteoarthritis than most regenerative injections. That does not make every injection inappropriate; it means an injection should complement a sound plan rather than replace it.
At Infinite Health, the purpose of a regenerative consultation is to determine whether the diagnosis, evidence, health history, and goals align—not to force every painful knee into the same procedure.
Who May—or May Not—Be a Reasonable Candidate?
A patient may be appropriate for a regenerative medicine discussion when knee pain has been properly evaluated, conservative measures have not provided acceptable function, and the patient understands the treatment’s investigational status and uncertainty.
An elective regenerative procedure may be inappropriate or need to wait when there is:
Suspected infection, fracture, or another urgent diagnosis
Unexplained severe swelling or systemic illness
Advanced instability or deformity requiring orthopedic assessment
A medical condition or medication that creates unacceptable procedural risk
An expectation of guaranteed cartilage regrowth or certain avoidance of surgery
Insufficient information about the exact product being proposed
The decision should be individualized and coordinated with orthopedic or other specialists when appropriate.
The Bottom Line
Regenerative medicine for knee pain is not one treatment, and the evidence cannot be summarized with a simple yes or no.
Dextrose prolotherapy has some human evidence suggesting symptom improvement, but study quality and protocols vary. Cell-based injections have produced mixed results, and high-quality analyses remain uncertain about their added clinical benefit. Wharton’s Jelly–derived products have limited, product-specific human evidence. Exosome research for knee osteoarthritis remains largely preclinical.
None of these approaches has been proven to reliably regrow knee cartilage, reverse osteoarthritis, prevent knee replacement, or produce a specific amount or duration of pain relief. No regenerative medicine product is FDA-approved to treat knee osteoarthritis or knee pain.
The most useful question is not “Does regenerative medicine work?” It is: What exactly is being proposed for my specific diagnosis, what evidence supports it, and what uncertainty am I accepting?
Get a Clear, Product-Specific Evaluation
If knee pain is limiting your work, travel, exercise, or daily life, start with a conversation focused on the diagnosis and the evidence—not a promise.
Schedule a free discovery call with an Infinite Health wellness coordinator to discuss your knee concerns, previous treatment, and goals. Virtual consultations are available for the initial evaluation when clinically appropriate and permitted based on your location; an in-person examination or procedure may still be required.
The free discovery call is not with the doctor, and is not a medical visit and does not include diagnosis, treatment recommendations, or prescribing.
Frequently Asked Questions
Does stem cell therapy actually work for knee pain?
Some studies report symptom improvement after certain cell-based injections, while more rigorous analyses find little or no clinically important benefit over controls. Products and protocols differ greatly, so the results cannot be applied to every treatment marketed as “stem cell therapy.”
Can regenerative medicine regrow knee cartilage?
No regenerative injection has been proven to reliably regrow normal knee cartilage in routine clinical care. Symptom improvement should not be presented as proof of structural regeneration.
Is prolotherapy FDA-approved for knee osteoarthritis?
Dextrose itself has medical uses, but prolotherapy is not an FDA-approved treatment for knee osteoarthritis. Research suggests possible pain and function benefits, but guidelines cite limited and inconsistent evidence.
Is Wharton’s Jelly the same as stem cells?
No. Wharton’s Jelly is umbilical-cord connective tissue. The contents of a final commercial product depend on how it is processed, and the label does not prove that viable mesenchymal stromal cells are present.
Are exosome injections FDA-approved for knee pain?
No. The FDA states that there are currently no FDA-approved exosome products, including for knee pain or osteoarthritis.
Can regenerative medicine prevent knee replacement?
That outcome has not been established. A procedure may or may not improve symptoms, but it should not be presented as a guaranteed way to delay or avoid surgery.
Can Infinite Health evaluate knee pain virtually?
An initial history and records review may be possible virtually when permitted by location and clinical circumstances. Knee pain often requires an in-person examination, imaging review, or procedure. A wellness coordinator can explain the current process during a free discovery call.
Medical and Regulatory Review Note
This article is educational and is not a substitute for medical advice, diagnosis, or treatment. It does not establish that any particular product is lawful, safe, or effective for a specific use. Product composition and regulatory status must be verified before publication and before any clinical use. The article requires physician and regulatory review because the FDA status and evidence for human cell, tissue, exosome, and related products are product- and indication-specific.
Sources
U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.
U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies.
Kolasinski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. 2020.
American Academy of Orthopaedic Surgeons. Use of Stem Cells in Orthopaedics.
Chen YW, et al. Effectiveness, Compliance, and Safety of Dextrose Prolotherapy for Knee Osteoarthritis. American Journal of Physical Medicine & Rehabilitation. 2022.
Rabago D, et al. Dextrose Prolotherapy for Knee Osteoarthritis: A Randomized Controlled Trial. Annals of Family Medicine. 2013.
Sadeghirad B, et al. Mesenchymal Stem Cells for Chronic Knee Pain Secondary to Osteoarthritis. Osteoarthritis and Cartilage. 2024.
Woolley K, et al. Evaluation of Spin in Clinical Trials of Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis. American Journal of Sports Medicine. 2025.
Aratikatla A, et al. Wharton’s Jelly and Osteoarthritis of the Knee. British Medical Bulletin. 2024.
Wang Z, et al. Mesenchymal Stem Cell–Derived Exosomes for the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis Based on Rat Models. Frontiers in Pharmacology. 2025.
Comments